BRAF and cancer: Although it was found that about 40% of human cancers were associated with aberrant ERK pathway activity, a recent review by Timofeev and collaborators cited the evidence that BRAF mutant CM, like A375 cells, are sensitive to ERK activation and overexpression of ERK has an inhibitory effect in this cell line [59].